Rezolute (RZLT) EBITDA (2012 - 2026)
Rezolute (RZLT) posted EBITDA of -$17.4 million for Q1 2026, up 28.3% sequentially from -$24.2 million in Q4 2025, and up 13.27% YoY from -$15.3 million in Q1 2025.
Rezolute (RZLT) EBITDA (2012 - 2026) Analysis & Trends
Rezolute has reported EBITDA for 15 years, with the latest figure at -$17.4 million in Q1 2026.
- Quarterly EBITDA rose 13.27% year-over-year to -$17.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$87.3 million (down 13.1% YoY) and the FY2025 annual result came in at -$79.9 million, down 13.45% from the prior year.
- EBITDA advanced to -$17.4 million in Q1 2026 per RZLT's latest filing, from -$24.2 million in the prior quarter.
- Over five years, EBITDA peaked at -$10.2 million in Q3 2022 and troughed at -$25.8 million in Q2 2025.
- A 5-year average of -$17.0 million and a median of -$16.9 million in 2024 frame the typical range for EBITDA.
- The sharpest annual moves came in 2022 and 2026: EBITDA plunged 96.13% in 2022, then climbed 13.27% in 2026.
- Over 5 years, EBITDA stood at -$14.4 million in 2022, then declined by 5.57% to -$15.2 million in 2023, then dropped by 12.41% to -$17.1 million in 2024, then sank by 41.81% to -$24.2 million in 2025, then increased by 28.3% to -$17.4 million in 2026.
- According to Business Quant data, EBITDA over the past three periods registered -$17.4 million, -$24.2 million, and -$19.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Rezolute | 442.94 Mn | 442.94 Mn | - | -17.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -17.37 Mn |
| Dec 31, 2025 | -24.22 Mn |
| Sep 30, 2025 | -19.82 Mn |
| Jun 30, 2025 | -25.85 Mn |
| Mar 31, 2025 | -20.02 Mn |
| Dec 31, 2024 | -17.08 Mn |
| Sep 30, 2024 | -16.94 Mn |
| Jun 30, 2024 | -23.10 Mn |
| Mar 31, 2024 | -16.21 Mn |
| Dec 31, 2023 | -15.19 Mn |
| Sep 30, 2023 | -15.91 Mn |
| Jun 30, 2023 | -14.24 Mn |
| Mar 31, 2023 | -17.14 Mn |
| Dec 31, 2022 | -14.39 Mn |
| Sep 30, 2022 | -10.22 Mn |
| Jun 30, 2022 | -11.30 Mn |
| Mar 31, 2022 | -10.75 Mn |
| Dec 31, 2021 | -12.15 Mn |
| Sep 30, 2021 | -7.64 Mn |
| Jun 30, 2021 | -6.64 Mn |